Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biotelliga is a New Zealand-based agricultural biotechnology company that specializes in the development of sustainable, fungal-based crop protection solutions. The company leverages its proprietary platform to identify and commercialize naturally occurring fungal endophytes and their bioactive metabolites, which provide targeted protection against a wide range of agricultural pests and diseases. By integrating these biological agents into existing farming practices, Biotelliga aims to significantly reduce the global reliance on synthetic chemical pesticides and fungicides. Their current portfolio includes advanced bio-insecticides and bio-fungicides targeting major threats such as the Diamondback moth and Botrytis. Following its acquisition by the Bridgewest Group, the company has expanded its research and manufacturing capabilities to support the global commercialization of its eco-friendly agricultural technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biotelliga Holdings.